Table 1.
Pharmacodynamic parameter estimates from the final population exposure‐response model for ACR20/50/70 in patients with rheumatoid arthritis on baricitinib
| Model parameter (units) |
Population mean (%SEE) |
95% Confidence interval from bootstrap analysis |
|---|---|---|
| Elimination rate constant Kout (week−1) | 0.171 (20.1) | (0.0839–0.450) |
| Half‐life for loss of placebo effect Tplb (hours) | 341 (56.3) | (5.99–6280) |
| Maximum ACRL effect Emax | 0.861 (3.22) | (0.264–0.897) |
| Concentration for half maximal ACRL effect EC50 (nM) | 68.0 (20.0) | (4.67–105) |
| Variance for BSV (logit scale) | 1.79 (11.5) | — |
ACR, American College of Rheumatology; ACR20/50/70 = 20%, 50%, and 70% improvement in ACR score, respectively; ACRL, ACR latent‐dependent variable; BSV, between‐subject variability; EC50, half‐maximal response concentration; Emax, maximal response; SEE, standard error of estimate; Tplb, half‐life of the placebo effect in hours.